Human trials could start soon on Adam’s 3D printed bone grafts

By

Adam — a young company with technology to 3D print bone grafts made out of ceramic bioglass and modified biopolymer — said today that it expects first human trials to start by the end of the year.

Officials at the Groton, Conn.– and Odessa, Ukraine–based company expect preclinical trials to finish this month. The Adam technology uses Kwambio printers and reduces the standard production cost of synthetic bones in half, from $0.12–$0.15/cm2 down to just $0.08.

Ideally, the bone graft dissolves as new bone grows, reducing the need for additional surgery, according to Adam.

If you want to read more about this news, click here. 

 

Posted in News, Science, Technology.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    18 junio, 2019

    More than 1 million Class I medical device units recalled in Q1

    For the third consecutive quarter, more than one million Class I units were recalled during 2019’s Q1. If you want to read more about this news click here. If you want to read more about this news click here.

  •
    10 octubre, 2019

    ‘Electronic tongues’ may help diagnose early stage bladder cancer

    New research presents a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. In a quest to find a better way of diagnosing bladder cancer, Spain-based researchers from the Polytechnic University of Valencia (UPV), the La Fe …

  •
    30 diciembre, 2019

    Medical Devices; Exemptions From Premarket Notification for Class I and Class II Devices

    «The Food and Drug Administration (FDA, Agency) identified a list of class I devices and class II devices that are now exempt from premarket notification requirements, subject to certain limitations. FDA published the lists of final determinations in accordance with procedures established by the 21stCentury Cures Act (Cures Act). Although each classification regulation for each …

  •
    30 diciembre, 2019

    Finding a non-invasive way to predict effectiveness of cancer therapy.

    «Researchers have taken a critical step toward developing a non-invasive nuclear medicine technique that can predict the effectiveness of therapy for cancerous tumors, allowing for personalized, precision treatment.» Read more.